After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Yahoo Finance discussed the stock recently as it posted Andrew Fisher Joins Verona Pharma as General Counsel.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
Verona Pharma Plc ADR is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of Verona Pharma Plc ADR is $1.37B. A total of 0.57 million shares were traded on the day, compared to an average of 493.73K shares.
In the most recent transaction, Rickard Kathleen A. sold 36,248 shares of VRNA for 2.22 per share on Feb 05 ’24. After the transaction, the Chief Medical Officer now owns 2,731,624 company shares. In a previous transaction on Nov 20 ’23, Edwards Martin bought 33,736 shares at 1.84 per share. VRNA shares that Director owns now total 144,800.
Among the insiders who bought shares, EBSWORTH DAVID R acquired of 160,000 shares on Nov 06 ’23 at a per-share price of $1.98. This resulted in the Director holding 844,643 shares of VRNA after the transaction. In another insider transaction, Rickard Kathleen A. sold 58,752 shares at $1.92 per share on Nov 03 ’23. Company shares held by the Chief Medical Officer now total 2,840,640.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, VRNA has a high of $23.81 and a low of $11.83.
As of this writing, VRNA has an earnings estimate of -$0.25 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of -$0.21 per share and a lower estimate of -$0.3. The company reported an EPS of -$0.18 in the last quarter, which was 35.70% higher than expectations of -$0.28.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. VRNA’s latest balance sheet shows that the firm has $148.38M in Cash & Short Term Investments as of fiscal 2021. There were $5.81M in debt and $33.42M in liabilities at the time. Its Book Value Per Share was $3.10, while its Total Shareholder’s Equity was $148.00M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRNA is Buy with a score of 5.00.
